BORIS - aBlação pOR mIcro-ondaS [Microwave Ablation] (BORIS)
Primary Purpose
Sarcoma
Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Image guided percutaneous microwave ablation
Sponsored by
About this trial
This is an interventional treatment trial for Sarcoma focused on measuring Sarcoma, Percutaneous ablation, Lung ablation, Microwave ablation
Eligibility Criteria
Inclusion Criteria:
- Patients over 18 years;
- Patients with lung metastases arising from sarcoma;
- Patients who are not eligible for surgery for medical reasons, including limited cardiopulmonary reserve. In this cases we will perform a pulmonary function test (PFT) to determine if the patient can withstand ablation;
- Patients with recurrent metastases after pneumectomy or metastases after surgical resection. In this cases we will perform a PFT to determine if the patient can withstand ablation;
- Patients with pulmonary lesions with dimensions up to 3,0 cm in the largest axial diameter;
- Patients with four or fewer lesions. In cases of bilateral metastases, we will evaluate the treatment of only one lung at a time, with an interval of at least two weeks for the treatment of the contralateral lung, respecting the clinical evolution of the patient.
- Patients with no extrapulmonary metastases or just indolent extrapulmonary disease;
- Patients with prior histopathological confirmation of pulmonary lesions.
Exclusion Criteria:
- Patients with primary disease without clinical control;
- Presence of uncontrolled extrapulmonary disease, including lymph node progression;
- Presence of hilar lesions or near the main bronchi;
- Presence of five or more lung lesions and/or lesions larger than 3,0 cm in greatest axial length;
- Presence of tumors infiltrating the chest wall, mediastinal and/or pleural dissemination;
- Patients with severe coagulopathy (international normalized ratio (INR) > 1,5 or lower platelet count to 50000/mm³);
- Patients with chronic obstructive pulmonary disease (COPD) stage III/ IV;
- Patients with septicemia;
- Patients refusing ablation treatment or participation in the study.
Sites / Locations
- Instituto do Câncer do Estado de São PauloRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Microwave ablation arm
Arm Description
Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation
Outcomes
Primary Outcome Measures
Overall Survival
Patients with sarcoma pulmonary metastases who are treated with microwave ablation of lung lesions may have higher overall survival rates compared to patients not subject to any kind of treatment or even chemotherapy/ palliative treatment. The literature contains data favorable to treating these patients with microwave ablation, since higher survival rates have been observed, especially when handled all lung lesions (R0).
Secondary Outcome Measures
Full Information
NCT ID
NCT04510714
First Posted
August 10, 2020
Last Updated
August 2, 2023
Sponsor
Instituto do Cancer do Estado de São Paulo
Collaborators
Angiodynamics, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04510714
Brief Title
BORIS - aBlação pOR mIcro-ondaS [Microwave Ablation]
Acronym
BORIS
Official Title
A Prospective, Phase III Study to Assess the Efficacy and Safety of Microwave Ablation of Metastatic Lung Sarcoma Lesions.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2023 (Actual)
Primary Completion Date
April 1, 2025 (Anticipated)
Study Completion Date
October 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto do Cancer do Estado de São Paulo
Collaborators
Angiodynamics, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients with sarcoma and lung metastases have few therapeutic options, with poor response to systemic treatment. Many of them are not eligible to surgical treatments due to the high number and distribution of pulmonary lesions or due to comorbidities, which reduce the survival chances of these individuals. Given the high efficacy and overall increased survival demonstrated by recent studies, the minimally invasive treatments (mainly radiofrequency ablation) have gained ground. Although the microwave ablation is a promising new technique for the treatment of patients with pulmonary metastases, there are few studies in the literature to evaluate the efficacy and safety of this procedure in the above population.
Detailed Description
This study was designed to prospectively evaluate the safety and effectiveness of microwave ablation therapy in the treatment of metastatic lung lesions secondary to sarcoma. This technique has been proven to be successful in producing greater areas of ablation, increasing the chances of success and reducing the possibility of local recurrence, especially when compared to radiofrequency ablation. There will be 60 consecutive patients diagnosed and treated at the oncology clinic at the São Paulo State Cancer Institute that are going to participate in this study, after meeting the inclusion/ exclusion criteria. This number may be increased up to approximately about 20 patients, according to the sample behavior in the initial analysis and follow-up. All patients will be informed about the benefits, risks, complications and limitations related to the procedure and written informed consent will be applied. Patients will also be informed that microwave ablation is a new technology in Brazil, despite the extensive international experience and the results already validated in the medical literature.
Logistic regression will be used to evaluate the success of the microwave ablation according to the characteristics of the lesion before the procedure. Logistic regressions for correlated data will be used to (a) evaluate the success of ablation according to all registered lesion characteristics, i.e., numeric characteristics (including tumor size and location) and categorical characteristics (histopathology of the primary tumor); (b) verify if combinations of two or more features of the lesions pose significant independent predictors for the success of ablation; and (c) construct a model to estimate the probability of success of the microwave ablation based on lesion characteristics before the procedure. The survival of patients will be assessed according to (a) the end result of the procedure (patients will be classified in two groups: an effective ablation group and a non-effective ablation group) and (b) the histopathological nature of the primary tumor. The survival rates will be calculated using the Kaplan-Meier test. The log-rank test (x² value of Cox-Mantel) will be used to determine statistically significant differences between the patients' survival rates. The value of P less than 0.05 will be considered to indicate a statistically significant difference for all analyses. Statistical software (Bias for Windows, version 8.4, Epsilon Verlag, Frankfurt, Germany) will be used.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoma
Keywords
Sarcoma, Percutaneous ablation, Lung ablation, Microwave ablation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Microwave ablation arm
Arm Type
Experimental
Arm Description
Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation
Intervention Type
Device
Intervention Name(s)
Image guided percutaneous microwave ablation
Other Intervention Name(s)
Image guided percutaneous lung metastasis ablation
Intervention Description
Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
Primary Outcome Measure Information:
Title
Overall Survival
Description
Patients with sarcoma pulmonary metastases who are treated with microwave ablation of lung lesions may have higher overall survival rates compared to patients not subject to any kind of treatment or even chemotherapy/ palliative treatment. The literature contains data favorable to treating these patients with microwave ablation, since higher survival rates have been observed, especially when handled all lung lesions (R0).
Time Frame
3 years
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients over 18 years;
Patients with lung metastases arising from sarcoma;
Patients who are not eligible for surgery for medical reasons, including limited cardiopulmonary reserve. In this cases we will perform a pulmonary function test (PFT) to determine if the patient can withstand ablation;
Patients with recurrent metastases after pneumectomy or metastases after surgical resection. In this cases we will perform a PFT to determine if the patient can withstand ablation;
Patients with pulmonary lesions with dimensions up to 3,0 cm in the largest axial diameter;
Patients with four or fewer lesions. In cases of bilateral metastases, we will evaluate the treatment of only one lung at a time, with an interval of at least two weeks for the treatment of the contralateral lung, respecting the clinical evolution of the patient.
Patients with no extrapulmonary metastases or just indolent extrapulmonary disease;
Patients with prior histopathological confirmation of pulmonary lesions.
Exclusion Criteria:
Patients with primary disease without clinical control;
Presence of uncontrolled extrapulmonary disease, including lymph node progression;
Presence of hilar lesions or near the main bronchi;
Presence of five or more lung lesions and/or lesions larger than 3,0 cm in greatest axial length;
Presence of tumors infiltrating the chest wall, mediastinal and/or pleural dissemination;
Patients with severe coagulopathy (international normalized ratio (INR) > 1,5 or lower platelet count to 50000/mm³);
Patients with chronic obstructive pulmonary disease (COPD) stage III/ IV;
Patients with septicemia;
Patients refusing ablation treatment or participation in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guilherme Lopes Pinheiro Martins, MD
Phone
+551138932000
Email
guilherme.martins@hc.fm.usp.br
First Name & Middle Initial & Last Name or Official Title & Degree
Lucas Fiore, MD
Phone
+551138932208
Email
lucas.fiore@hc.fm.usp.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcos Roberto de Menezes, MD, PHD
Organizational Affiliation
Instituto do Cancer do Estado de Sao Paulo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Instituto do Câncer do Estado de São Paulo
City
São Paulo
ZIP/Postal Code
01246-000
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guilherme Lopes Pinheiro Martins, Md
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make IPD available
Citations:
PubMed Identifier
22012906
Citation
Vogl TJ, Naguib NN, Gruber-Rouh T, Koitka K, Lehnert T, Nour-Eldin NE. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology. 2011 Nov;261(2):643-51. doi: 10.1148/radiol.11101643. Erratum In: Radiology. 2013 Mar;266(3):1000.
Results Reference
background
PubMed Identifier
17626404
Citation
Abbas G, Schuchert MJ, Pennathur A, Gilbert S, Luketich JD. Ablative treatments for lung tumors: radiofrequency ablation, stereotactic radiosurgery, and microwave ablation. Thorac Surg Clin. 2007 May;17(2):261-71. doi: 10.1016/j.thorsurg.2007.03.007.
Results Reference
background
PubMed Identifier
12376615
Citation
Dupuy DE, Mayo-Smith WW, Abbott GF, DiPetrillo T. Clinical applications of radio-frequency tumor ablation in the thorax. Radiographics. 2002 Oct;22 Spec No:S259-69. doi: 10.1148/radiographics.22.suppl_1.g02oc03s259.
Results Reference
background
PubMed Identifier
18372457
Citation
Wolf FJ, Grand DJ, Machan JT, Dipetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. 2008 Jun;247(3):871-9. doi: 10.1148/radiol.2473070996. Epub 2008 Mar 27.
Results Reference
background
PubMed Identifier
10628454
Citation
Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000 Jan;174(1):57-9. doi: 10.2214/ajr.174.1.1740057. No abstract available.
Results Reference
background
PubMed Identifier
17392258
Citation
Simon CJ, Dupuy DE, DiPetrillo TA, Safran HP, Grieco CA, Ng T, Mayo-Smith WW. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007 Apr;243(1):268-75. doi: 10.1148/radiol.2431060088.
Results Reference
background
PubMed Identifier
16366374
Citation
Suh R, Reckamp K, Zeidler M, Cameron R. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology (Williston Park). 2005 Oct;19(11 Suppl 4):12-21.
Results Reference
background
PubMed Identifier
19514086
Citation
Nakamura T, Matsumine A, Yamakado K, Matsubara T, Takaki H, Nakatsuka A, Takeda K, Abo D, Shimizu T, Uchida A. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas [corrected]. Cancer. 2009 Aug 15;115(16):3774-81. doi: 10.1002/cncr.24420. Erratum In: Cancer. 2009 Sept 1;115(17):4041.
Results Reference
background
PubMed Identifier
19767303
Citation
Ding JH, Chua TC, Glenn D, Morris DL. Feasibility of ablation as an alternative to surgical metastasectomy in patients with unresectable sarcoma pulmonary metastases. Interact Cardiovasc Thorac Surg. 2009 Dec;9(6):1051-3. doi: 10.1510/icvts.2009.218743. Epub 2009 Sep 18.
Results Reference
background
PubMed Identifier
22564777
Citation
Lu Q, Cao W, Huang L, Wan Y, Liu T, Cheng Q, Han Y, Li X. CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases. World J Surg Oncol. 2012 May 7;10:80. doi: 10.1186/1477-7819-10-80.
Results Reference
background
Learn more about this trial
BORIS - aBlação pOR mIcro-ondaS [Microwave Ablation]
We'll reach out to this number within 24 hrs